Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids

Karishma Desai; Ian Carroll; Steven M. Asch; Tina Hernandez‐Boussard; John P A Ioannidis

doi:10.1016/j.jclinepi.2018.10.012

Back

Shared by

John P A Ioannidis

Stanford University

Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids

Article 2018 en

Authors

KD
Karishma Desai
IC
Ian Carroll
SA
Steven M. Asch

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2016

Comparative rates of harms in randomized trials from more developed versus less developed countries may be different

Despina G. Contopoulos‐Ioannidis, Xanthippi Tseretopoulou, Megan Ancker, Juan N. Walterspiel, Orestis A. Panagiotou, Yvonne Maldonado, John P A Ioannidis

Article2017

Comparative evidence on harms in pediatric randomized clinical trials from less developed versus more developed countries is limited

Dario Tedesco, Mufiza Farid‐Kapadia, Martin Offringa, Zulfiqar A Bhutta, Yvonne Maldonado, John P A Ioannidis, Despina G. Contopoulos‐Ioannidis

Article2014

Comparative effect sizes in randomised trials from less developed and more developed countries: a meta-epidemiological assessment

Orestis A. Panagiotou, Despina G. Contopoulos‐Ioannidis, John P A Ioannidis

Article2013

Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment

Orestis A. Panagiotou, Despina G. Contopoulos‐Ioannidis, John P A Ioannidis

Article2025

Trustworthiness and Transparency Features Were Less Frequent in Randomized Trials Presenting Large Effects in Abstracts

Jonathan Henssler, Joana Reis‐Pardal, Lina Koppel, John P A Ioannidis